LEIDEN, The Netherlands and SEATTLE, June 17, 2010 ProFibrix B.V., a leader in the development of innovative products forhemostasis and regenerative medicine, today announced that it has enteredinto an agreement with CSL Behring for the clinical and commercial supply ofplasma-based fibrinogen and thrombin, for the manufacturing of Fibrocaps(TM).CSL Behring is a leader in the plasma protein therapeutics industry and asubsidiary of CSL Limited (ASX: CSL), a global biopharmaceutical companyheadquartered in Melbourne, Australia.
Jaap Koopman, CEO of ProFibrix said: "We are extremely pleased with thesupply agreement with CSL Behring. CSL Behring is one of the acknowledgedglobal leaders in the plasma protein therapeutic industry. Importantly, theagreement will enable us to use CSL Behring's fibrinogen and thrombin,approved in markets around the world, as active components in our leadproduct Fibrocaps. This will offer us a tremendous advantage with regulatoryauthorities when seeking approval for Fibrocaps."
Fibrocaps is based on a mixture of two essential blood clotting proteins,fibrinogen and thrombin, and is a unique dry powder topical tissue sealant indevelopment to stop bleeding after or during surgery. Fibrocaps is clearlydifferentiated from existing liquid tissue sealants and hemostats: it isready for immediate use, is stable at room temperature, and has shown to besafe and efficacious in the first Phase II study conducted in EU. ProFibrixis starting a global Phase II study in the summer of 2010.
ProFibrix (http://www.ProFibrix.com) was founded in 2004 and isheadquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA,USA. The company leverages its expertise in fibrinogen technology to developand market innovative products for the hemostasis and regenerative medicinemarkets. Human fibrinogen plays a pivotal role in blood clotting and tissuehealing. ProFibrix is led by a team with extensive commercial, clinical andscientific experience in the hemostasis field.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry.Committed to saving lives and improving the quality of life for people withrare and serious diseases, the company manufactures and markets a range ofplasma-derived and recombinant therapies worldwide. CSL Behring therapies areindicated for the treatment of coagulation disorders including hemophilia andvon Willebrand disease, primary immune deficiencies, inherited respiratorydisease and hereditary angioedema. The company's products are also used incardiac surgery, organ transplantation, burn treatment and to preventhemolytic diseases in newborns. CSL Behring operates one of the world'slargest plasma collection networks, CSL Plasma. CSL Behring is a subsidiaryof CSL Limited (ASX: CSL), a biopharmaceutical company headquartered inMelbourne, Australia. For more information, visit http://www.cslbehring.com.
SOURCE ProFibrix B.V.